No Data
No Data
Buy Rating Affirmed for Precision BioSciences on Strong Pipeline and Market Potential
Express News | Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Express News | HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
Precision BioSciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 395.87% HC Wainwright & Co. → $60 Reiterates Buy → Buy 04/30/2024 57.02% Guggenheim → $19 Initi
Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Adicet Bio (ACET)
Maintaining Hold on Precision BioSciences Pending Clinical Data and Strategic Reassessments